D. E. Shaw & Co. Inc. Has $12.04 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

D. E. Shaw & Co. Inc. grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 9.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 286,079 shares of the biopharmaceutical company’s stock after acquiring an additional 24,485 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Ultragenyx Pharmaceutical were worth $12,035,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in Ultragenyx Pharmaceutical by 17.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 346,597 shares of the biopharmaceutical company’s stock valued at $14,581,000 after purchasing an additional 51,874 shares during the last quarter. Driehaus Capital Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 5.8% in the fourth quarter. Driehaus Capital Management LLC now owns 829,465 shares of the biopharmaceutical company’s stock valued at $34,896,000 after buying an additional 45,521 shares during the period. Deep Track Capital LP bought a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $27,493,000. Crestline Management LP acquired a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth approximately $1,176,000. Finally, Cutter Capital Management LP grew its holdings in Ultragenyx Pharmaceutical by 41.8% during the 4th quarter. Cutter Capital Management LP now owns 406,803 shares of the biopharmaceutical company’s stock worth $17,114,000 after acquiring an additional 120,000 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Activity

In related news, CFO Howard Horn sold 1,785 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares in the company, valued at $4,289,227.60. This represents a 1.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares of the company’s stock, valued at $2,116,156.50. This trade represents a 1.89% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 125,405 shares of company stock worth $5,285,169. Company insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $35.40 on Wednesday. The firm has a market cap of $3.35 billion, a PE ratio of -5.58 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a 52-week low of $29.59 and a 52-week high of $60.37. The business’s 50 day moving average price is $36.67 and its two-hundred day moving average price is $42.11.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The company had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business’s revenue was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.03) EPS. Research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on RARE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. JPMorgan Chase & Co. raised their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Canaccord Genuity Group raised their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Finally, Morgan Stanley upped their target price on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an “overweight” rating in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $90.93.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.